Ben Taylor

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.

Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis.

Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team.

Aetion, Inc. provides data analytics software solutions. The firm?s Aetion Evidence Platform enables life sciences customers to transform disparate data sets into evidence needed to make critical business decisions; and helps payers determine effective treatments for specific patient populations and measure impact in outcomes and utilization. The company was founded by Jeremy A. Rassen, Sebastian Schneeweiss and Allon Rauer in 2013 and is headquartered in New York, NY.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.